Literature DB >> 8824223

mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect.

G Hateboer1, E M Hijmans, J B Nooij, S Schlenker, S Jentsch, R Bernards.   

Abstract

Adenovirus E1A encodes two nuclear phosphoproteins that can transform primary rodent fibroblasts in culture. Transformation by E1A is mediated at least in part through binding to several cellular proteins, including the three members of the retinoblastoma family of growth inhibitory proteins. We report here the cloning of a novel murine cDNA whose encoded protein interacts with both adenovirus type 5 and type 12 E1A proteins. The novel E1A-interacting protein shares significant sequence homology with ubiquitin-conjugating enzymes, a family of related proteins that is involved in the proteasome-mediated proteolysis of short-lived proteins. Highest homology was seen with a Saccharomyces cerevisiae protein named UBC9. Importantly, the murine E1A-interacting protein complements a cell cycle defect of a S. cerevisiae mutant which harbors a temperature-sensitive mutation in UBC9. We therefore named this novel E1A-interacting protein mUBC9. We mapped the region of E1A that is required for mUBC9 binding and found that the transformation-relevant conserved region 2 of E1A is required for interaction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8824223     DOI: 10.1074/jbc.271.42.25906

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  The sentrin-conjugating enzyme mUbc9 interacts with GLUT4 and GLUT1 glucose transporters and regulates transporter levels in skeletal muscle cells.

Authors:  F Giorgino; O de Robertis; L Laviola; C Montrone; S Perrini; K C McCowen; R J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  Two classes of human papillomavirus type 16 E1 mutants suggest pleiotropic conformational constraints affecting E1 multimerization, E2 interaction, and interaction with cellular proteins.

Authors:  T Yasugi; M Vidal; H Sakai; P M Howley; J D Benson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  Human pathogens and the host cell SUMOylation system.

Authors:  Peter Wimmer; Sabrina Schreiner; Thomas Dobner
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  Transformation by E1A oncoprotein involves ubiquitin-mediated proteolysis of the neuronal and tumor repressor REST in the nucleus.

Authors:  Hancheng Guan; Robert P Ricciardi
Journal:  J Virol       Date:  2012-03-14       Impact factor: 5.103

5.  Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation.

Authors:  Puck Knipscheer; Willem J van Dijk; Jesper V Olsen; Matthias Mann; Titia K Sixma
Journal:  EMBO J       Date:  2007-05-10       Impact factor: 11.598

Review 6.  Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes.

Authors:  Peter Pelka; Jailal N G Ablack; Gregory J Fonseca; Ahmed F Yousef; Joe S Mymryk
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein.

Authors:  M R Campanero; E K Flemington
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  RanBP2 associates with Ubc9p and a modified form of RanGAP1.

Authors:  H Saitoh; R Pu; M Cavenagh; M Dasso
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

9.  Covalent modification of the transactivator protein IE2-p86 of human cytomegalovirus by conjugation to the ubiquitin-homologous proteins SUMO-1 and hSMT3b.

Authors:  H Hofmann; S Flöss; T Stamminger
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

10.  Covalent modification of the homeodomain-interacting protein kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1.

Authors:  Y H Kim; C Y Choi; Y Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.